Environmental tobacco smoke and bladder cancer risk in never smokers of Los Angeles County

Cancer Research

Volumn 67, Issue 15, 2007, Pages 7540-7545

  Jiang, Xuejuan ^b   Yuan, Jian Min ^a,d   Skipper, Paul L ^c   Tannenbaum, Steven R ^c   Yu, Mimi C ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 BIPHENYLAMINE; TOBACCO SMOKE;

ADULT; ARTICLE; BLADDER CANCER; CANCER RISK; CASE CONTROL STUDY; CIGARETTE SMOKING; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENVIRONMENTAL EXPOSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; SPOUSE; STATISTICAL SIGNIFICANCE; UNITED STATES;

ADULT; AMINOBIPHENYL COMPOUNDS; ENVIRONMENTAL EXPOSURE; FEMALE; HEMOGLOBINS; HUMANS; LOS ANGELES; MALE; MIDDLE AGED; PHENOTYPE; RISK FACTORS; TOBACCO SMOKE POLLUTION; URINARY BLADDER NEOPLASMS;

EID: 34547633099     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0048     Document Type: Article

References (40)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Yu MC, Ross RK. Bladder cancer: epidemiology. In: Bertino JR, editor. Encyclopedia of cancer. 2nd ed. Vol. I. San Diego: Academic Press; 2002. p. 215-21.
3. Talaska G, Schamer M, Skipper P, et al. Detection of carcinogen-DNA adducts in exfoliated urothelial cells of cigarette smokers: association with smoking, hemoglobin adducts, and urinary mutagenicity. Cancer Epidemiol Biomarkers Prev 1991;1:61-6.
4. Phillips DH. Smoking-related DNA and protein adducts in human tissues. Carcinogenesis 2002;23:1979-2004.
5. Borgerding MF, Bodnar JA, Wingate DE. The 1999 Massachusetts benchmark study, final report. A research study conducted after consultation with the Massachusetts Department of Public Health. Massachusetts: Department of Health; 2000.
6. Takenawa J, Kaneko Y, Okumura K, Nakayama H, Fujita J, Yoshida O. Urinary excretion of mutagens and covalent DNA damage induced in the bladder and kidney after passive smoking in rats. Urol Res 1994;22:93-7.
7. Izzotti A, Bagnasco M, D'Agostini F, et al. Formation and persistence of nucleotide alterations in rats exposed whole-body to environmental cigarette smoke. Carcinogenesis 1999;20:1499-505.
8. Hammond S, Coghlin J, Gann P, et al. Relationship between environmental tobacco smoke exposure and carcinogen-hemoglobin adduct levels in nonsmokers. J Natl Cancer Inst 1993;85:474a-8.
9. Maclure M, Katz R, Bryant M, Skipper P, Tannenbaum S. Elevated blood levels of carcinogens in passive smokers. Am J Public Health 1989;79:1381-4.
10. Bartsch H, Caporaso N, Coda M, et al. Carcinogen hemoglobin adducts, urinary mutagenicity, and metabolic phenotype in active and passive cigarette smokers. J Natl Cancer Inst 1990;82:1826-31.
11. Bos RP, Theuws JL, Henderson PT. Excretion of mutagens in human urine after passive smoking. Cancer Lett 1983;19:85-90.
12. U.S. Environmental Protection Agency. Respiratory health effects of passive smoking: lung cancer and other disorders. Washington (DC): U.S. Environmental Protection Agency Office of Research and Development, Publication EPA/600/690/006F; 1992.
13. Kabat GC, Dieck GS, Wynder EL. Bladder cancer in nonsmokers. Cancer 1986;57:362-7.
14. Burch JD, Rohan TE, Howe GR, et al. Risk of bladder cancer by source and type of tobacco exposure: a casecontrol study. Int J Cancer 1989;44:622-8.
15. Sandler DP, Everson RB, Wilcox AJ. Passive smoking in adulthood and cancer risk. Am J Epidemiol 1985;121:37-48.
16. Zeegers MP, Goldbohm RA, van den Brandt PA. A prospective study on active and environmental tobacco smoking and bladder cancer risk (The Netherlands). Cancer Causes Control 2002;13:83-90.
17. Samanic C, Kogevinas M, Dosemeci M, et al. Smoking and bladder cancer in Spain: effects of tobacco type, timing, environmental tobacco smoke, and gender. Cancer Epidemiol Biomarkers Prev 2006;15:1348-54.
18. Castelao JE, Yuan JM, Skipper PL, et al. Gender- and smoking-related bladder cancer risk. J Natl Cancer Inst 2001;93:538-45.
19. Bernstein L, Ross RK. Cancer in Los Angeles County. Los Angeles (CA): University of Southern California; 1991.
20. Skipper PL. Precision and sensitivity of aminobiphenyl hemoglobin adduct assays in a long-term population study. J Chromatogr B Analyt Technol Biomed Life Sci 2002;778:375-81.
21. Skipper PL, Tannenbaum SR, Ross RK, Yu MC. Nonsmoking-related arylamine exposure and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 2003;12:503-7.
22. Castelao JE, Yuan JM, Gago-Dominguez M, Yu MC, Ross RK. Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 2000;82:1364-9.
23. Gago-Dominguez M, Castelao JE, Yuan JM, Yu MC, Ross RK. Use of permanent hair dyes and bladder-cancer risk. Int J Cancer 2001;91:575-9.
24. Castelao JE, Yuan JM, Gago-Dominguez M, et al. Carotenoids/vitamin C and smoking-related bladder cancer. Int J Cancer 2004;110:417-23.
25. Skipper PL, Tannenbaum SR. Protein adducts in the molecular dosimetry of chemical carcinogens. Carcinogenesis 1990;11:507-18.
26. Rockhill B, Newman B, Weinberg C. Use and misuse of population attributable fractions. Am J Public Health 1998;88:15-9.
27. Tang D, Warburton D, Tannenbaum SR, et al. Molecular and genetic damage from environmental tobacco smoke in young children. Cancer Epidemiol Biomarkers Prev 1999;8:427-31.
28. Mollerup S, Ryberg D, Hewer A, Phillips DH, Haugen A. Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients. Cancer Res 1999;59:3317-20.
29. Yu MC, Ross RK, Chan KK, et al. Glutathione S-transferase M1 genotype affects aminobiphenylhemoglobin adduct levels in white, black and Asian smokers and nonsmokers. Cancer Epidemiol Biomarkers Prev 1995;4:861-4.
30. Engel LS, Taioli E, Pfeiffer R, et al. Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: a HuGE review. Am J Epidemiol 2002; 156:95-109. Erratum in: Am J Epidemiol 2002;156:492.
31. Garcia-Closas M, Malats N, Silverman D, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses [see comment]. Lancet 2005;366:649-59.
32. Curtin F, Morabia A, Bernstein M. Lifetime exposure to environmental tobacco smoke among urban women: differences by socioeconomic class. Am J Epidemiol 1998;148:1040-7.
33. Borland R, Pierce JP, Burns DM, Gilpin E, Johnson M, Bal D. Protection from environmental tobacco smoke in California. The case for a smoke-free workplace. JAMA 1992;268:749-52.
34. Hammond SK, Sorensen G, Youngstrom R, Ockene JK. Occupational exposure to environmental tobacco smoke. JAMA 1995;274:956-60.
35. Johnson KC, Hu J, Mao Y. Lifetime residential and workplace exposure to environmental tobacco smoke and lung cancer in never-smoking women, Canada 1994-97. Int J Cancer 2001;93:902-6.
36. Jenkins RA, Counts RW. Personal exposure to environmental tobacco smoke: salivary cotinine, airborne nicotine, and nonsmoker misclassification. J Expo Anal Environ Epidemiol 1999;9:352-63.
37. Jenkins RA, Palausky MA, Counts RW, Guerin MR, Dindal AB, Bayne CK. Determination of personal exposure of non-smokers to environmental tobacco smoke in the United States. Lung Cancer 1996;14 Suppl 1:S195-213.
38. Jurek AM, Greenland S, Maldonado G, Church TR. Proper interpretation of non-differential misclassification effects: expectations vs observations. Int J Epidemiol 2005;34:680-7.
39. Vineis P. Epidemiology of cancer from exposure to arylamines. Environ Health Perspect 1994;102 Suppl 6:7-10.
40. Turesky RJ, Freeman JP, Holland RD, et al. Identification of aminobiphenyl derivatives in commercial hair dyes. Chem Res Toxicol 2003;16:1162-73.